Capricor Therapeutics, Inc. (CAPR)
- Sector
- Biotechnology
- Last price
- $6.59
- As of
Kresmion compiles this page from CAPR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CAPRICOR THERAPEUTICS, INC. (CAPR): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-24.
See the full CAPR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CAPR on one page. Preview it with sample data, then open it live with a free account.
Preview the CAPR dossierActive signals for CAPR
- highCONSENSUS_BUY
3 tracked funds increased CAPR this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 16.3%, EPS $-0.70 vs $-0.6018 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +66% to CAPR (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 88% of CAPR (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 65% of CAPR (2026Q2)
FREE, NO ACCOUNT
Every signal on CAPR, as it fires
You are seeing 5 of 11 signals recorded on CAPR since 2026-06-09.
The five above landed across 3 days. The other 6 were recorded on 2 other days. 6 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CAPR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 14070B309 · 2026Q2 | $19.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 14070B309 · 2026Q2 | $5.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 14070B309 · 2026Q2 | $3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 14070B309 · 2026Q2 | $2.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CAPR
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CAPR against its peers
CAPR's return on equity of -34.4% ranks in the 68th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | CAPR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 7.3M USD | 14 | 13 |
| Operating margin | n/a | -472.0% | n/a | 10 |
| Net margin | n/a | -310.8% | n/a | 10 |
| Return on equity | -34.4% | -50.5% | 68 | 19 |
| 1 year | n/a | -19.2% | n/a | 15 |
Peers (20): TECX, AUTL, RZLT, ENTX, PRTA, YDES, EPRX, DMAC, ASMB, OVID, ZURA, ARVN, SPRY, NGNE, MPLT, OCS, ALT, MYGN, KYTX, MNPR. Left out: AGMB (no annual filing), PRTC (period gap), EIKN (no annual filing), DRUG (period gap), TRXB (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CAPR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CAPR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CAPR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.